Research programme: anticancer therapeutics - Bellus Health

Drug Profile

Research programme: anticancer therapeutics - Bellus Health

Alternative Names: ECO 02201; ECO-2201; ECO-3396; ECO-7942; TLN-05220; TLN-05223

Latest Information Update: 21 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ecopia BioSciences
  • Class Bacteria; Enediynes; Polyketide synthases; Proteins; Small molecules
  • Mechanism of Action DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 21 Aug 2013 No development reported - Preclinical for Cancer in Canada (SC)
  • 21 Aug 2013 No development reported - Preclinical for Cancer in France (SC)
  • 15 Aug 2013 Thallion Pharmaceuticals has been acquired and merged into BELLUS Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top